Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System.
The Purpose of this multi centre clinical data evaluation is to document the performance and clinical outcomes of the Comprehensive Segmental revision System. The data gathered will be collated and used to provide feedback to designing engineers, support marketing efforts, answer potential questions from reimbursement agencies, and will serve as part of Zimmer Biomets Post Market Surveillance. The Comprehensive Segmental Revision System consists of a proximal humeral replacement system (shoulder prosthesis), a distal humeral replacement system (elbow prosthesis) and of a total humeral replacement system (shoulder and elbow prosthesis connected by a humeral coupler). Patient outcomes will be measured by using measurement tools that have been extensively used and referred to in the literature. Specifically, the quickDASH will be used for all cases enrolled in the study. In addition, the Constant and Murley Score may be used for shoulder applications, the Liverpool Elbow Score may be used for elbow applications and the MSTS Score may be used for tumor cases. The study population will be compromised of males and females that are eligible according to the inclusion/exclusion criteria. The study will last for at least ten (10) years from the time of surgery.
Study Type
OBSERVATIONAL
Enrollment
105
This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Department of Orthopedic Surgery, Rigshospitalet University of Copenhagen
Copenhagen, Denmark
Royal Gwent Hospital
Newport, Wales, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
Implant survivorship assessed according to the implant revisions
Implant survivorship assessed counting the number of implant revisions
Time frame: 10 years
Clinical patient outcome measure: QuickDASH
The QuickDASH score will be used to measure physical function and symptoms of the upper limb in patients to be treated/treated with the Comprehensive SRS products.
Time frame: Pre-operative and at 6 months, 1 year, 3 years and 5 years post-operative
Clinical patient outcome measure: Constant-Murley Score
The Constant-Murley score may be used to define the level of pain and the ability to carry out the normal daily activities in patients to be treated/treated with the Comprehensive SRS products. The score consists of objective (ROM, strength) and subjective (pain, functional assessment) variables.
Time frame: Pre-operative and at 6 months, 1 year, 3 years and 5 years post-operative
Clinical patient outcome measure: Liverpool Elbow Score
The Liverpool Elbow Score may be used to define elbow condition, function and pain in patients to be treated/treated with the Comprehensive SRS products.The score consists of two components: one patient-rated part and another part that can be measured objectively.
Time frame: Pre-operative and at 6 months, 1 year, 3 years and 5 years post-operative
Clinical patient outcome measure: Musculoskeletal Tumour Society Scoring System (MSTS)
The MSTS Score may be used as a functional measure for patients with sarcoma involving the upper limb. The score includes 6 measures (pain, function, emotional acceptance, hand position, manual dexterity, lifting ability) each measure with a maximum of 5 points. The maximum overall score is 30 points. The score is designed to be used after the procedure and is therefore only collected post-operatively.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 months, 1 year, 3 years and 5 years post-operative
Safety is assessed according to the number of complications
Safety is assessed according to the number of complications which are collected via adverse event forms
Time frame: 10 years